In U.S. health care, structure quietly taxes patients: when the same corporate parent owns the doctor, the hospital, the insurer, and the pharmacy middleman, the bill often rises while outcomes fail to improve. The evidence points to a simple, durable truth—market power and payment design, not medical necessity, drive too many dollars.
The Short Version
- Rigorous analyses find physician-hospital integration rarely improves patient outcomes and can make them worse, even as prices rise.
- Integrated systems gain leverage to raise unit prices, switch to higher-paying billing venues, and steer referrals to owned facilities.
- Research synthesized for federal regulators links vertical consolidation to higher prices without proven quality offsets; some physician specialties saw double-digit price jumps after acquisitions.
- Breaking up mega-firms is not a silver bullet; entry barriers like Certificate of Need laws also entrench incumbents and blunt competition.
What vertical integration in health care actually does
Vertical integration combines entities at different steps of care—hospitals with physician groups, insurers with clinics, pharmacy benefit managers (PBMs) with pharmacies. Its promise is coordination: shared records, tighter handoffs, fewer duplicative markups. Its reality, in many markets, is financial engineering that exploits payment rules. Economists at the Federal Trade Commission (FTC) analyzed the effects of physician-hospital integration on Medicare beneficiaries’ outcomes and reached an unambiguous conclusion: vertical integration rarely leads to better health outcomes and sometimes results in worse outcomes. That matters because Medicare is the most data-rich, standard-priced laboratory we have; if coordination gains were large and routine, this is where they would show up.
Why do costs still rise? Mechanism, not mystique. When a hospital acquires a physician practice, three things tend to change. First, the system’s bargaining power increases; payers face a “must-have” hospital tied to its physician network, which can drive higher unit prices. Second, identical services migrate from the physician office to the hospital outpatient department, where facility fees and payment differentials inflate the bill. Third, referrals steer to owned labs, imaging centers, and post-acute affiliates even when independent options are cheaper—an internal transfer that looks like care coordination but functions like revenue capture. These channels were documented in the St. Luke’s/Saltzer litigation record and related FTC materials.
The price effects are consistent—and they are not offset by quality
Across comment dockets and literature syntheses assembled for federal rulemaking, a recurring finding emerges: vertical consolidation in outpatient and physician services increases prices without demonstrable improvements in measured quality. Recent regulatory submissions go further, citing claims data showing post-acquisition price increases—for example, an average 11% rise in dermatology, gastroenterology, and ophthalmology prices following private-equity roll-ups from 2016 to 2020. Prices that climb with no measured clinical gain are not integration succeeding; they are market power expressing itself through reimbursement design.
This is not an abstract worry limited to hospital-physician deals. The same economic logic runs through conglomerates that combine insurers, physician groups, PBMs, and pharmacies under one roof. When the parent company pays itself across the transaction chain and keeps rebate flows inside the house, the opportunities for self-preference and opaque cross-subsidies multiply—even if each affiliate looks defensible in isolation. That structural conflict makes it harder for outside competitors to win on price or service and harder for payers and patients to know whether any “savings” flowed through.
Fairly weighing the counter-case: where integration can help—and when it does not
Health economics does recognize genuine efficiencies from integration. Eliminating double markups between stages of production can lower total premiums; shared infrastructure can reduce transaction costs; aligned incentives can ease clinical coordination. A balanced review therefore cannot declare all vertical integration harmful on its face. The more careful conclusion, reflected in academic surveys, is conditional: integration can lower prices in some settings, but it can also increase them when it enhances market power or exploits payment differentials. The FTC’s outcome study and multiple policy syntheses show the latter dynamic dominates in many U.S. provider markets today.
That pattern calls for precision in remedies. A blanket decree to break up every vertically integrated firm outruns the evidence. Yet so does complacency that integration is inherently patient-beneficial. The durable lesson is to target the mechanisms that turn coordination into cash extraction: site-of-service payment gaps, steering rules, exclusive contracting that locks up physician networks, and opaque internal transfer pricing. Where those levers cannot be fixed by conduct rules alone, structural separation becomes the cleanest way to remove the conflict.
Market rules can entrench the problem—and must be reformed in parallel
Even the most artful divestiture will disappoint if new entrants cannot get to market. Needs-based entry restrictions such as Certificate of Need (CON) laws limit the number of suppliers, confer pricing power on incumbents, and let entrenched systems delay or block rivals—a dynamic documented by the OECD and echoed in U.S. policy testimony. Certificates of Public Advantage (COPAs) can compound the harm by shielding otherwise-illegal mergers from antitrust scrutiny under state supervision.
Congressional testimony by economist Martin Gaynor outlines a pragmatic competition agenda: roll back rules that inadvertently incentivize consolidation—CON statutes, rigid scope-of-practice limits that suppress innovative care models, licensing barriers that impede telehealth and interstate entry—and stop using COPAs to launder monopolies. Reciprocity in licensing and a posture that protects patients rather than incumbents would lower the ramp for independent physician groups, urgent care chains, and ambulatory surgery centers to contest local markets. Integration is easier to discipline when rivals can actually enter.
What a serious policy package looks like
A credible, evergreen reform program marries structural clarity with market-opening rules. First, neutralize the billing arbitrage: adopt site-neutral payments so the same service is paid the same rate regardless of venue, removing the incentive to buy practices simply to flip claims into higher-paying settings. Second, police referral steering and exclusive contracts that foreclose independent competitors; where internal data or merger review uncovers systematic self-dealing that inflates spending, pursue conduct remedies with teeth or targeted separations limited to the offending vertical link. Third, dismantle regulatory barriers that block new capacity—repeal or sharply narrow CON, sunset COPAs, expand licensure reciprocity, and modernize scope-of-practice to enable lower-cost clinicians and telehealth to compete.
Finally, insist on empirical accountability. If a system claims integration will reduce avoidable admissions or lower total cost of care, bind those claims to measurable targets in risk-bearing contracts and claw back payments when they miss. Regulators and researchers should exploit natural experiments—site-neutral reforms, court-ordered divestitures, and acquisitions that go through with behavioral conditions—to compare prices, referral patterns, and outcomes against matched controls. One submission’s finding of an 11% specialty price increase after acquisitions is exactly the kind of signal that should trigger targeted scrutiny and, where needed, structural relief.
Bottom line
Vertical integration in American health care is not a morality play about size; it is a technical story about leverage, billing rules, and who captures the surplus. The best evidence shows many integrations raise prices without improving health. The right answer is not performative trust-busting or blind tolerance, but disciplined, mechanism-driven policy: close the payment loopholes that reward buy-and-bill strategies, open markets so challengers can enter, and separate only where conflicts predictably tax patients. Do those three things together, and the structure of care will serve the patient rather than the parent company.
Sources:
reason.com, search.ftc.gov, smith.edu, downloads.regulations.gov, ftc.gov
